Sugi Predict

Sugi Predict / Compounds / SCHEMBL5364

SCHEMBL5364

SCHEMBL5364

C=C1CCC(C(=O)OCC)CC1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.49
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ ALDH1A1 P00352 6/20 0.46
▸ PDK1 Q15118 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ PPM1B O75688 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PPP1CC P36873 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665962 0.89 PDK1 (0.49) MAPTALOX15TSHRMAPK1ALDH1A1
SCHEMBL13553943 0.89 MAPT (0.46) MAPTALOX15TSHRMAPK1ALDH1A1
SCHEMBL17468752 0.89 TSHR (0.43) MAPTALOX15TSHRMAPK1ALDH1A1
Ethylene SCHEMBL4705578 0.83 ALDH1A1 (0.49) MAPTALOX15TSHRMAPK1ALDH1A1
SCHEMBL5483 0.82 ALDH1A1 (0.51) MAPTALOX15TSHRMAPK1ALDH1A1
SCHEMBL880077 0.82 ALDH1A1 (0.41) TSHRMAPK1ALDH1A1SMN1; SMN2PPM1B
SCHEMBL8891623 0.81 MAPT (0.60) MAPTALDH1A1MEN1KMT2APPM1B
SCHEMBL2375356 0.81 MAPT (0.60) MAPTALDH1A1MEN1KMT2APPM1B
SCHEMBL4221 0.81 — —
SCHEMBL237380 0.81 MAPT (0.60) MAPTALDH1A1MEN1KMT2APPM1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624044-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-05-12 — — US disclosed
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof ALECTOS THERAPEUTICS 1NC (CA) 2026-04-28 — — US disclosed
US-12606568-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-04-21 — — US disclosed
EP-3966199-B1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC (CA) 2026-03-18 — — EP disclosed
WO-2025106788-A1 PI3Kα INHIBITORS AND METHODS OF MAKING AND USING THE SAME RELAY THERAPEUTICS, INC. (US) 2025-05-22 — — WO disclosed
US-20250109138-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-03 — — US disclosed
CN-119678921-A Cyclohexene derivative with attraction effect on carpiotosia borer as well as preparation method and application thereof 华东理工大学 2025-03-25 — — CN disclosed
WO-2025026283-A1 COMPOUND FOR SELECTIVELY DEGRADING SMARCA2/4 AND USE THEREOF 甘李药业股份有限公司 2025-02-06 — — WO disclosed
CN-114174263-B Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2025-01-10 — — CN disclosed
CN-119241504-A Spiroindoline inhibitors of KIF18A 沃拉斯查疗法公司 2025-01-03 — — CN disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 — — US disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 — — US disclosed
WO-2008084300-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER PRODUCTS INC. (US) 2008-07-17 — — WO disclosed
WO-2008084300-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER PRODUCTS INC. (US) 2008-07-17 — — WO disclosed
US-20080108595-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2008-05-08 — — US disclosed
US-7314872-B2 Inhibitors of cathepsin S IRM LLC (BM) 2008-01-01 — — US disclosed
EP-1658267-A4 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2007-08-01 — — EP disclosed
EP-1658267-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2006-05-24 — — EP disclosed
US-20050113356-A1 Inhibitors of cathepsin S IRM LLC (BM) 2005-05-26 — — US disclosed
WO-2005034848-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2005-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE SPTLC1, SPTLC2, CPT1A MAPT 1776/4885ALOX15 827/4885TSHR 2038/4885
US-20080108595-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ MAPT 1757/4885ALOX15 2978/4885TSHR 3750/4885
US-12612380-B2 Non-lysosomal glucosylceramidase inhibitors and uses thereof GBA1, GBA2, MAN2B1 MAPT 4517/4885ALOX15 4246/4885TSHR 866/4885
US-20050113356-A1 Inhibitors of cathepsin S CTSS, CTSB, CTSZ MAPT 1757/4885ALOX15 2978/4885TSHR 3750/4885
US-12624044-B2 SMARCA degraders and uses thereof SMARCA1, SMARCC1, SMARCA2 MAPT 2169/4885ALOX15 4768/4885TSHR 2477/4885
US-12606568-B2 SMARCA degraders and uses thereof SMARCA1, SMARCD1, SMARCC1 MAPT 724/4885ALOX15 4743/4885TSHR 2649/4885
US-20250109138-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 MAPT 3823/4885ALOX15 4270/4885TSHR 4388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.